ELISA Detection for Mouse Models of Mastitis: Analytes, Protocols, and Applications

ELISA detection in mouse models of mastitis provides quantitative measurement of inflammatory cytokines, oxidative stress markers, tight junction proteins, and immune mediators in serum, plasma, and mammary gland tissue homogenates. This technical article describes the standard analyte panels, sample preparation workflows, assay methodologies, and preclinical applications of ELISA testing for LPS-induced and bacteria-induced murine mastitis models. Researchers in anti-inflammatory drug development, functional food evaluation, and mechanistic studies rely on these validated immunoassays to quantify disease severity and therapeutic efficacy.

Technical Overview

Mastitis is an inflammatory disease of the mammary gland, typically caused by bacterial infection or endotoxin exposure, and is widely studied in preclinical research using murine models. The most common experimental models include lipopolysaccharide (LPS)-induced mastitis, Staphylococcus aureus-induced mastitis, and Escherichia coli-induced mastitis, typically established in lactating or non-lactating female BALB/c or C57BL/6 mice via intramammary (intraductal) infusion through the teat canal of the fourth abdominal mammary gland.

Enzyme-linked immunosorbent assay (ELISA) is the core quantitative platform for evaluating these models. It enables sensitive and specific measurement of soluble biomarkers that reflect the magnitude of the inflammatory response, blood-milk barrier integrity, oxidative damage, and immune modulation following therapeutic intervention. ELISA data are typically interpreted alongside histopathological scoring of mammary tissue (hematoxylin-eosin staining), myeloperoxidase (MPO) activity assays, and qPCR confirmation of gene-level expression.

ELISA procedures performed in accredited third-party laboratories follow recognized quality frameworks, including ISO/IEC 17025 general requirements for the competence of testing and calibration laboratories, along with kit-specific validation criteria covering calibration, precision, and recovery.

Testing Samples

Serum

Blood is collected at endpoint via retro-orbital puncture, submandibular bleeding, or cardiac puncture under anesthesia. After clotting at room temperature for 30–60 minutes, samples are centrifuged at approximately 3,000 rpm for 10–15 minutes at 4 °C. The separated serum is aliquoted and stored at −80 °C to avoid repeated freeze-thaw cycles. Serum is used for systemic cytokines (TNF-α, IL-1β, IL-6), acute phase proteins, and immunoglobulin analysis.

Plasma

Plasma is obtained using anticoagulants such as heparin or EDTA, followed by centrifugation within 30 minutes of collection. It is suitable for analytes where clotting-related degradation is a concern. Hemolyzed or lipemic specimens are flagged or rejected, as interference may compromise optical density readings at 450 nm.

Mammary Gland Tissue Homogenate

The harvested fourth mammary gland is rinsed in cold PBS, blotted, weighed, and homogenized in PBS or RIPA buffer (typically 1:9 or 1:10 w/v). Homogenates are centrifuged at 10,000–12,000 × g for 10–15 minutes at 4 °C, and the supernatant is collected for ELISA. Total protein concentration is determined by BCA or Bradford assay so that tissue analyte results can be normalized and reported as pg/mg protein or ng/g tissue.

Milk and Whey Fractions

In lactating models, milk can be collected following oxytocin administration. Whey is prepared by centrifuging milk to remove the fat layer and casein pellet, and is used for secretory IgA (sIgA), lactoferrin, and antimicrobial peptide measurement.

Cell Culture Supernatants

Primary mammary epithelial cells or macrophages (e.g., RAW264.7 or primary peritoneal macrophages) stimulated with LPS ex vivo provide supernatants for cytokine ELISA, supporting mechanistic correlation between in vivo and in vitro findings.

Testing Items

The analyte menu for murine mastitis model ELISA testing is organized into functional biomarker panels:

Pro-inflammatory Cytokines

• TNF-α (tumor necrosis factor-alpha)
• IL-1β (interleukin-1 beta)
• IL-6 (interleukin-6)
• IL-17A (interleukin-17A)
• IL-18 (interleukin-18)
• IL-12/IL-23p40
• KC/CXCL1 (functional murine IL-8 homolog)
• MCP-1/CCL2 (monocyte chemoattractant protein-1)

Anti-inflammatory and Immunomodulatory Cytokines

• IL-4 (interleukin-4)
• IL-10 (interleukin-10)
• TGF-β1 (transforming growth factor-beta 1)
• IL-13 (interleukin-13)

Blood-Milk Barrier and Tight Junction Proteins

• ZO-1 (zonula occludens-1)
• Occludin
• Claudin-1 and Claudin-3
• Soluble intercellular adhesion molecule-1 (sICAM-1)
• Vascular endothelial growth factor (VEGF)

Signaling Pathway Proteins

• TLR4 (Toll-like receptor 4)
• MyD88 (myeloid differentiation primary response 88)
• NF-κB p65 and phosphorylated p65 (p-p65)
• IκBα and phosphorylated IκBα
• NLRP3 inflammasome-associated proteins
• HMGB1 (high mobility group box 1)

Oxidative Stress Markers

• Superoxide dismutase (SOD)
• Glutathione peroxidase (GSH-Px)
• Glutathione (GSH) and glutathione disulfide (GSSG)
• Catalase (CAT)
• Malondialdehyde (MDA)
• Total antioxidant capacity (T-AOC)
• 8-iso-prostaglandin F2α (8-iso-PGF2α)

Acute Phase Proteins and Immune Globulins

• C-reactive protein (CRP)
• Serum amyloid A (SAA)
• Immunoglobulins IgG, IgM, and secretory IgA (sIgA)
• Lactoferrin
• Complement C3

Marker Combinations for Model Validation

• Core triad for inflammation confirmation: TNF-α + IL-1β + IL-6
• Barrier integrity panel: ZO-1 + occludin + claudin-1
• Pathway activation panel: TLR4 + MyD88 + p-NF-κB p65
• Redox homeostasis panel: SOD + GSH-Px + MDA + T-AOC

Testing Methods

Double-Antibody Sandwich ELISA

Sandwich ELISA is the primary format for cytokines, tight junction proteins, and pathway proteins. Capture antibodies pre-coated on 96-well microplates bind the target analyte in standards and samples. A biotinylated detection antibody and streptavidin-HRP conjugate complete the immune complex. After TMB substrate development and sulfuric acid stop solution, absorbance is read at 450 nm with 570 nm or 630 nm wavelength correction. Concentrations are interpolated from a four-parameter logistic (4PL) standard curve, with typical assay sensitivity in the low pg/mL to ng/mL range depending on the analyte.

Competitive and Indirect ELISA

Competitive ELISA is applied to small-molecule analytes such as MDA or lipid peroxidation products with a single epitope. Indirect ELISA formats are used for antibody titer assessment in vaccine or immunization studies.

Sample Preparation and Quality Control

• Samples are thawed on ice and mixed gently; duplicate or triplicate wells are recommended.
• Tissue homogenates undergo BCA protein quantification for normalization to total protein.
• Kit controls include blank wells, zero standards, and internal quality control sera.
• Accepted runs require standard curve R² ≥ 0.99 and QC recovery within 80–120%.
• Samples exceeding the upper limit of quantification are diluted and re-assayed.

Methodological Validation Parameters

• Limit of detection (LOD) and limit of quantification (LOQ) established from blank plus three and ten standard deviations, respectively
• Intra-assay precision (CV < 10%) and inter-assay precision (CV < 15%)
• Spiking recovery (80–120%) and dilution linearity for matrix effects
• Cross-reactivity verification to ensure murine specificity of antibodies
• Parallelism testing between diluted samples and calibration standards

Turnaround and Reporting

Standard ELISA panels for a completed study can typically be reported within 5–10 working days after sample receipt. Reports include raw optical density data, calculated concentrations, standard curves, QC results, normalization factors, and interpretation relative to control groups (normal control, model control, and treated groups).

Applications

Anti-Inflammatory Drug Screening

Reduction of TNF-α, IL-1β, and IL-6 in LPS-challenged mice is a primary pharmacodynamic endpoint for non-steroidal anti-inflammatory candidates, biologics, and small-molecule inhibitors targeting the TLR4/NF-κB axis.

Natural Product and Functional Food Research

Plant extracts, polysaccharides, flavonoids, probiotics, and functional dairy components are evaluated for their capacity to suppress pro-inflammatory cytokines, restore antioxidant enzyme activity (SOD, GSH-Px, CAT), and reduce MDA in mammary tissue.

Mechanistic Pathway Studies

ELISA quantification of TLR4, MyD88, p-IκBα, and p-NF-κB p65 supports pathway inhibition studies, complemented by Western blotting and immunohistochemistry for full mechanistic confirmation.

Blood-Milk Barrier Protection Research

Upregulation of ZO-1, occludin, and claudins following intervention demonstrates protective effects on mammary tight junctions and vascular permeability during endotoxin challenge.

Vaccine and Immunomodulator Development

Antibody titer measurement by indirect ELISA, combined with cytokine profiling and bacterial load determination in mammary tissue, supports evaluation of mastitis vaccine candidates and immunostimulatory adjuvants.

Publication and Regulatory Support

Validated ELISA datasets from accredited third-party laboratories support peer-reviewed publication, grant applications, and preclinical study documentation aligned with ISO/IEC 17025 quality principles.

FAQ

Why choose ELISA over qPCR or Western blotting for mastitis mouse models?

ELISA directly quantifies secreted, biologically active protein levels in serum and tissue homogenates, whereas qPCR measures mRNA transcripts that may not correlate with secreted protein. ELISA also offers higher throughput, quantitative standard curves, and simpler workflows than Western blotting, making it ideal for multi-group, multi-analyte preclinical studies.

Which mouse strain and model are most commonly used?

Female BALB/c or C57BL/6 mice are most common. The LPS-induced model (typically 50 μg LPS from E. coli serotype O55:B5 infused into the fourth mammary gland duct) is preferred for cytokine-focused studies, while live S. aureus or E. coli suspensions are used for infection-driven models.

How is tissue cytokine data normalized between samples?

Mammary homogenate results are normalized to total protein measured by BCA assay, and expressed as pg of analyte per mg of total protein. This corrects for variations in tissue size and homogenization efficiency across animals.

What sample volume is required per analyte?

Most commercial murine ELISA kits require 50–100 μL of sample per well. For multiplexing several analytes from limited serum volumes (mice yield roughly 300–800 μL of serum), low-volume protocols or repeated bleeding schedules are used.

Can ELISA distinguish phosphorylated from total pathway proteins?

Yes. Phospho-specific ELISA kits capture phosphorylated epitopes such as p-NF-κB p65 (Ser536) or p-IκBα, and running both total and phospho-protein assays enables calculation of activation ratios.

What if analyte concentrations fall below the detection limit?

Samples below LOD are reported as undetectable, and options include sample concentration, use of high-sensitivity kits, or switching to platforms with lower LODs for scarce analytes such as certain murine interleukins.

How should samples be shipped to the testing laboratory?

Serum, plasma, and tissue homogenate supernatants should be stored at −80 °C and shipped on dry ice with temperature monitoring, accompanied by a sample manifest listing collection times, anticoagulant type, and animal group assignments.

What statistical approaches are standard for ELISA data?

Data are typically analyzed by one-way ANOVA followed by Tukey or Dunnett post hoc tests, with results presented as mean ± SEM. Non-parametric alternatives such as Kruskal-Wallis tests are applied when distributions are non-normal.